The Future of Venetoclax in Waldenstrom's

Venetoclax clearly has activity in this disease. Waldenstrom's patients have a lot of BCL2 to inhibit. And Venetoclax is active, even though it's not first line yet. There are trials out there of Bortezimib, Abrutinibrotuximab and CXCR4 inhibitors. For many indolent lymphomas, we always worry about transformation to lazzo lymphoma.